Kinetic properties of the primary inhibitor of plasmin from human plasma.

No abstract is available for this paper.

• Publication year

  1977

• Venue

  Biochemical Journal

• Publication date

  1977-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1042/BJ1630389PMID 141280PMCID PMC1164709
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ELEMENTARY STEPS IN ENZYME REACTIONS (AS STUDIED BY RELAXATION SPECTROMETRY).

  2006cited by this paper
• Kinetic studies of the urokinase catalysed conversion of NH2-terminal lysine plasminogen to plasmin.

  1977cited by this paper
• Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

  1976cited by this paper
• The primary inhibitor of plasmin in human plasma.

  1976cited by this paper
• Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

  1976cited by this paper
• Immunochemical distinction between antiplasmin and alpha-antitrypsin.

  1975cited by this paper
• pH effects in plasmin-catalysed hydrolysis of alpha-N-benzoyl-L-arginine compounds.

  1975cited by this paper
• Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.

  1974cited by this paper
• Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes.

  1969cited by this paper

• Enhancing Hemocompatibility in ECMO Systems With a Fibrinolytic Interactive Coating: in Vitro Evaluation of Blood Clot Lysis Using a 3D Microfluidic Model

  2025cites this paper
• Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target

  2022cites this paper
• Improving Hemocompatibility: How Can Smart Surfaces Direct Blood To Fight against Thrombi.

  2021cites this paper
• Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.

  2016cites this paper
• Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity

  2016cites this paper
• Natural heterogeneity of alpha-2-antiplasmin : functional and clinical consequences

  2015cites this paper
• Effects of Extracellular DNA on Plasminogen Activation and Fibrinolysis*

  2011cites this paper
• The plasmin–antiplasmin system: structural and functional aspects

  2011cites this paper
• The human α2-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region

  2010cites this paper
• The past, present and future of plasmin inhibitor.

  2005influential citation
• Thrombolysis: Scientific Basis for Current Therapy

  2005cites this paper
• Chapter 12 – Disorders of the Hematopoietic System

  2004cites this paper
• Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with α2-antiplasmin

  2003cites this paper
• Structural/functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide.

  2003cites this paper
• Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin.

  2002cites this paper
• GENE TARGETING IN HEMOSTASIS

  2002cites this paper
• Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

  2001cites this paper
• Gene targeting in hemostasis. Alpha2-antiplasmin.

  2001cites this paper
• Functional Consequences of Differences in Carbohydrate Sequences of Fetal and Adult Plasminogen and Fibrinogen

  2001cites this paper
• Analysis of plasminogen activator inhibitor type 2 (PAI-2) expression on the cell surface of monocytic cell lines and human peripheral blood leukocytes

  2000cites this paper
• Hereditary Defects in Fibrinolysis Associated with Thrombosis

  1999cites this paper
• Effect of Phenylglyoxal-modified α2-Antiplasmin on Urokinase-induced Fibrinolysis

  1998cites this paper
• Reaction of human α2‐antiplasmin and plasmin Stopped‐flow fluorescence kinetics

  1996cites this paper
• Reaction of human alpha2-antiplasmin and plasmin stopped-flow fluorescence kinetics.

  1996cites this paper
• Prodrugs of peptides and peptidomimetics for improved formulation and delivery

  1996cites this paper
• Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.

  1995cites this paper
• A relationship between trypsin and plasmin inhibitors and sialyltransferase activity

  1994cites this paper
• Dissociation of alpha 2-plasmin-inhibitor-plasmin complex and regeneration of plasmin activity by SDS treatment.

  1993cites this paper
• Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.

  1993cites this paper
• The Dissociation of α2-Plasmin-Inhibitor-Plasmin Complex to Active Plasmin by SDS Treatment

  1993cites this paper
• Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.

  1993cites this paper
• Prodrugs of peptides and proteins for improved formulation and delivery.

  1993cites this paper
• 6 Mechanism of action of the thrombolytic agents

  1990cites this paper
• Chapter 8 – Relationship between Plasminogen Receptors and Lp(a)

  1990cites this paper
• Mechanism of action of the thrombolytic agents.

  1990cites this paper
• Platelet alpha 2-antiplasmin.

  1989cites this paper
• Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.

  1989cites this paper
• Plasminogen activation: biochemistry, physiology, and therapeutics.

  1988cites this paper
• Studies on biosynthesis of α2-antiplasmin in rat liver cells

  1988cites this paper
• Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.

  1988cites this paper
• Plasminogen Activators: Molecular Properties, Biological Cell Function and Clinical Application

  1988cites this paper
• The cell-binding domains of plasminogen and their function in plasma.

  1988cites this paper
• Fibrin-specific thrombolytic agents.

  1988cites this paper
• Studies on biosynthesis of alpha 2-antiplasmin in rat liver cells.

  1988cites this paper
• Pharmacodynamic and Systemic Fibrinolytic Effects of Plasminogen Activators in Man

  1988cites this paper
• Fibrin-specific thrombolytic therapy.

  1988cites this paper
• Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant

  1987cites this paper
• Fibrinspezifische thrombolytische Substanzen

  1987cites this paper
• Photoaffinity labeling of human plasmin and plasminogen.

  1987cites this paper
• The reactive site of human alpha 2-antiplasmin.

  1987cites this paper
• Amino‐acid sequence of human α2‐antiplasmin

  1987cites this paper
• Molecular mechanisms of fibrinolysis and their application to fibrin‐specific thrombolytic therapy

  1987cites this paper
• Amino-acid sequence of human alpha 2-antiplasmin.

  1987cites this paper
• Studies on alpha 2-plasmin inhibitor fragment T-11. I. Synthesis of the protected hexadecapeptide ester corresponding to positions 11 through 26 of alpha 2-plasmin inhibitor fragment T-11.

  1987cites this paper
• Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).

  1987cites this paper
• Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.

  1987cites this paper
• Fibrin-specific thrombolytic agents.

  1987cites this paper
• Fibrin-specific thrombolytic agents.

  1987cites this paper
• Concepts of clot lysis.

  1986cites this paper
• Fibrinolysis: Its initiation and regulation

  1986cites this paper
• The fibrinolytic system in man.

  1986cites this paper
• Topography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe.

  1986cites this paper
• Thrombolytic therapy in the eighties.

  1986cites this paper
• Chapter 8 Fibrinolysis and thrombolysis

  1986cites this paper
• α2-Plasmin inhibitor: Inhibitory regulator of fibrinolytic system

  1986cites this paper
• [Current views on structure and function of alpha2-antiplasmin].

  1985cites this paper
• Chapter 11. Plasminogen Activators

  1985cites this paper
• Molecular mechanism of fibrinolysis.

  1984cites this paper
• Theory and experimental method for determining individual kinetic constants of fast-acting, irreversible proteinase inhibitors.

  1984cites this paper
• The fibrinolytic system in man.

  1984cites this paper
• An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.

  1984cites this paper
• The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function.

  1984cites this paper
• Thrombosis and Cardiovascular Disease

  1984cites this paper
• Inhibitors of the Fibrinolytic Enzyme System

  1984cites this paper
• The Fibrinolytic Enzyme System

  1983cites this paper
• Adaptation of acyl-enzyme kinetic theory and an experimental method for evaluating the kinetics of fast-acting, irreversible protease inhibitors.

  1983cites this paper
• Human plasma proteinase inhibitors.

  1983cites this paper
• Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation.

  1983cites this paper
• Relationships among the complement, kinin, coagulation and fibrinolytic systems in the inflammatory reaction.

  1983cites this paper
• Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin

  1982cites this paper
• The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.

  1982cites this paper
• The fibrinolytic system and its relation to inflammatory diseases.

  1982cites this paper
• Kinetics of the Inhibition of Plasmin in Acidified Human Plasma

  1982cites this paper
• Preparation and properties of covalent compounds and intermediates of serine proteases.

  1982cites this paper
• The Suitability of Various Plasmin Preparations for the Functional Assay of α2-Antiplasmin in Plasma

  1982cites this paper
• Studies on the mechanism of the antifibrinolytic action of tranexamic acid.

  1981cites this paper
• On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin.

  1981cites this paper
• Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitor.

  1981cites this paper
• Demonstration of two forms of alpha 2-antiplasmin in plasma by modified crossed immunoelectrophoresis.

  1981cites this paper
• Properties of three different molecular forms of the alpha 2 plasmin inhibitor.

  1981cites this paper
• Immunochemical characterization of the kringle 4 fragment of human plasminogen.

  1981cites this paper
• Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

  1981cites this paper
• Potential for Thrombolytic Therapy

  1981cites this paper
• The lysine binding sites of human plasminogen. Evidence for a critical tryptophan in the binding site of kringle 4.

  1981cites this paper
• Activation of Glu-plasminogen by urokinase in the presence of fibrinogen, fibrin, and SK-potentiator.

  1981cites this paper
• Influence of SK-potentiator and fibrinogen degradation products on the activation of human plasminogen by streptokinase.

  1981cites this paper
• [32] Human α2-antiplasmin☆

  1981cites this paper
• [30] Human plasmin

  1981cites this paper
• Properties of Three Different Molecular Forms of the α2Plasmin Inhibitor

  1981cites this paper
• Human plasmin.

  1981cites this paper